Request Demo

Last update 08 May 2025

Influenza Virus Like Particle Vaccines(University Of Washington)

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Virus-like particle vaccine, Prophylactic vaccine

Synonyms

Influenza VLP vaccines - Icosavax, Research programme: influenza virus like particle vaccines - Icosavax, influenza virus like particle vaccines(University of Washington)

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

University of Washington

Active Organization

Icosavax, Inc.

National Institutes of Health

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

100 Clinical Results associated with Influenza Virus Like Particle Vaccines(University Of Washington)

100 Translational Medicine associated with Influenza Virus Like Particle Vaccines(University Of Washington)

100 Patents (Medical) associated with Influenza Virus Like Particle Vaccines(University Of Washington)

Literatures (Medical) associated with Influenza Virus Like Particle Vaccines(University Of Washington)

01 Dec 2017·Microbes and InfectionQ3 · MEDICINE

Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice

Q3 · MEDICINE

Article

Author: Yang, Chinglai ; Ye, Ling ; Wen, Zhiyuan ; Dong, Ke ; Bu, Zhigao ; Zhang, Huizhong ; Wang, Xi

Elderly humans over 65 years old are at great risk to pathogenesis by influenza virus infection. However, although influenza vaccines provide effective protection in healthy young adults, protection of elderly adults is substantially lower even with a good match between the vaccine and the circulating influenza virus. To gain insight of the underlying mechanism for the reduced immunogenicity of influenza vaccines in the aged population, we investigated immunogenicity of influenza virus-like particle vaccines in aged mice, which represent a useful model for studying aging associated impairment in immune responses. Specifically, we investigated the effect of inhibiting regulatory T cells in aged mice on induction of protective immune responses by influenza vaccines. Our results showed that injecting anti-CD25 antibodies could down-regulate CD25 on the surface of regulatory T cells and significantly increase the levels of antibody responses induced by VLP immunization in aged mice. Further, the profiles of antibody responses were also changed towards Th1 type by regulatory T cell blockage in aged mice. Moreover, aged mice that were treated by anti-CD25 antibodies prior to vaccination were more effectively protected against lethal influenza virus challenge.

02 Oct 2016·Expert Review of VaccinesQ2 · MEDICINE

Progress in developing virus-like particle influenza vaccines

Q2 · MEDICINE

Review

Author: Kang, Sang-Moo ; Kim, Min-Chul ; Kim, Ki-Hye ; Lee, Young-Tae ; Quan, Fu-Shi

Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.

01 Jan 2014·Clinical and Experimental Vaccine Research

Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use

Review

Author: Lee, Dong-Hun ; Park, Jae-Keun ; Song, Chang-Seon

Virus-like particles (VLPs), which resemble infectious virus particles in structure and morphology, have been proposed to provide a new generation of vaccine candidates against various viral infections. As effective immunogens, characterized by high immunogenicity and safety, VLPs have been employed in the development of human influenza vaccines. Recently, several influenza VLP vaccines have been developed for veterinary use and successfully evaluated in swine, canine, duck, and chicken models. These VLP vaccine candidates induced protective immune responses and enabled serological differentiation between vaccinated and infected animals in conjunction with a diagnostic test. Here, we review the current progress of influenza VLP development as a next-generation vaccine technology in the veterinary field and discuss the challenges and future direction of this technology.

100 Deals associated with Influenza Virus Like Particle Vaccines(University Of Washington)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 1	United States	Icosavax, Inc.	31 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Influenza Virus Like Particle Vaccines(University Of Washington)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation